Natera net worth in 2024 is a topic of interest for anyone tracking the growth of this biotech leader. At Ando Money, we provide a professional analysis of Natera’s financial performance.
From its revenue growth to test volumes, our deep dive covers everything you need to know about this evolving company’s financial journey.
Quick Facts
| FACT | DETAIL |
|---|---|
| Name | Natera, Inc. |
| Full Name | Natera, Inc. |
| Website | www.natera.com |
| Industry | Biotechnology, Genetic Testing |
| Traded as | NASDAQ: NTRA |
| ISIN | US6323071042 |
| Founded | 2003 |
| Founders | Matthew Rabinowitz, Jonathan Sheena |
| Country/Territory | United States |
| Headquarters | Austin, Texas |
| Chief Executive Officer | Steve Chapman |
| Number of Employees | Approximately 3,400 |
| Market Cap | $15.55 billion (Oct 2024) |
| Total Assets | $1.52 billion |
| Total Equity | $836.5 million |
| Revenue | $413.4 million (Q2 2024) |
| Net Income | -$37.5 million (Q2 2024) |
What is the Net Worth/Market Cap Of Natera in 2024?
As of October 2024, Natera’s market capitalization is estimated at $15.55 billion.
This places it among the top biotech companies globally. In comparison to its peers, Natera has shown substantial growth, particularly in revenue and product performance.
The company’s strategic positioning in the genetic testing industry helps maintain its competitive edge. When looking at similar entities, Natera’s financial growth stands tall. Below are a few related companies in this space:
- Guardant Health
- Invitae
- Foundation Medicine
- Myriad Genetics
- Thermo Fisher Scientific
- Illumina
- 10x Genomics
- Roche Diagnostics
For more details on how companies rank, visit our feature on leading global companies.
Natera Financial Performance Overview
Revenue Growth and Key Drivers
In the second quarter of 2024, Natera generated $413.4 million in total revenue, representing a 58.1% increase compared to the same period in 2023.
The company’s focus on product revenues, which amounted to $411.4 million, was a major contributor to this growth. This performance was largely driven by increased test volumes and higher selling prices.
By expanding its genetic testing services, particularly in oncology, prenatal, and organ health, Natera has successfully broadened its market reach.
Test Volumes and Impact on Earnings
Natera processed around 760,300 tests in Q2 2024, reflecting a 23.2% increase compared to the same period in 2023.
This rise in test volumes contributed significantly to the company’s earnings, particularly in its oncology segment.
For example, approximately 125,400 oncology tests were performed during this quarter. The strong demand for these services has led to higher revenue per test, further bolstering the company’s financial results.
Gross Margin Analysis
Natera’s gross margin improved to 58.8% in Q2 2024, up from 45.2% in the prior year. This improvement is due to several factors, including higher revenues and cost management initiatives.
By controlling production expenses and improving operational efficiency, the company has been able to achieve greater profitability.
Additionally, better pricing strategies and cash collections for previously delivered tests contributed to this impressive margin growth.
Operating Expenses and Their Impact on Financials
The company’s operating expenses reached $287.1 million in Q2 2024, reflecting a 24.4% increase year over year.
Research and development (R&D) expenses climbed as Natera continued to invest in expanding its test portfolio.
Furthermore, selling, general, and administrative expenses grew due to headcount increases and higher consulting and legal costs.
While operating costs have risen, these investments are aligned with Natera’s long-term growth strategy.
Cash Flow and Debt Management
Natera achieved positive cash flow of $3.3 million in Q2 2024. The company held approximately $887.1 million in cash, cash equivalents, and short-term investments as of June 30, 2024.
Despite holding a debt of $364.0 million, Natera has managed its debt obligations effectively, particularly through its convertible senior notes and UBS line of credit.
This financial flexibility allows the company to continue pursuing growth initiatives while managing its debt load responsibly.
Financial Forecast and Outlook
Looking ahead, Natera projects 2024 revenues between $1.49 billion and $1.52 billion.
The company expects gross margins to remain strong, ranging between 54% to 56% for the full year.
Natera also anticipates spending approximately $350 to $375 million on research and development, underlining its commitment to innovation.
With its expanding product offerings and strong market position, Natera is well-positioned for continued growth.
FAQs About Natera
What types of tests does Natera offer?
It provides genetic testing services across three primary areas: oncology, women’s health, and organ health. Its offerings include tests for cancer detection, prenatal screenings, and organ transplant monitoring.
How has its gross margin improved in 2024?
Its gross margin increased to 58.8% in Q2 2024, up from 45.2% in the same period the previous year. The margin growth is attributed to increased revenues, improved cost management, and efficient operational practices.
What is Natera’s cash position in 2024?
As of June 30, 2024, Natera held $887.1 million in cash, cash equivalents, and short-term investments. This healthy cash position has supported the company’s growth and strategic initiatives.
How many tests did Natera process in Q2 2024?
It processed approximately 760,300 tests in the second quarter of 2024, an increase of 23.2% compared to the same period in 2023. This includes oncology, prenatal, and organ health tests.
Conclusion
Natera continues to showcase strong financial growth and innovation in the biotech sector.
We invite you to explore more financial insights and engage with our content at Ando Money. Don’t hesitate to leave a comment or share your thoughts!
